Wei Z. Ai

MD PhD

Oncologist
Lymphoma specialist and amateur yoga enthusiast

About me

Dr. Wei Ai is a blood cancer specialist who cares for adults with conditions such as Hodgkin's lymphoma and non-Hodgkin's lymphoma, including cutaneous lymphomas, which primarily involve the skin. She also sees patients needing blood and bone marrow transplantation.

In her research, Ai focuses on novel approaches to lymphoma treatment, especially targeted agents for T-cell lymphomas. Her studies often lead to clinical trials of new therapies that target cancer at the molecular level.

Ai earned a doctoral degree in microbiology and immunology as well as her medical degree from Stanford University School of Medicine. She completed a residency in internal medicine at UCSF, followed by fellowship training in medical oncology at Stanford.

  • Education

    Stanford University School of Medicine, 2000

  • Residencies

    UCSF Medical Center, 2002

  • Fellowships

    UCSF Medical Center, Bone Marrow Transplant, 2003

    Stanford Hospital and Clinics, Medical Oncology, 2005

  • Academic Title

    Professor

Cutaneous Lymphoma Clinic

1701 Divisadero St., Fourth Floor
San Francisco, CA 94143

Hematology and Blood and Marrow Transplant

400 Parnassus Ave., Fourth Floor
San Francisco, CA 94143

My reviews

4.9

Overall Experience
163 Reviews
I came to Dr Ai because she explained everything to me even when I wasn't her patient. Since I have been her patient she has shown not only great professional care but warmth and understanding.
Explained things in a way that was easy to understand
161 Reviews
Did the doctor pay attention to your concerns
163 Reviews
Gave easy to understand instructions about taking care of health problems or concerns
160 Reviews
Knew the important information about your medical history
163 Reviews
The provider showed respect for what you had to say
163 Reviews
The provider spent enough time with me
161 Reviews

Selected research

Decorative Caduceus

Safety and Efficacy of Tenalisib (RP6530) in Combination With Romidepsin in Patients With Relap...

The MTD was defined as the highest dose level at which no more than 1 in 6 participants experienced a dose-limiting toxicity (DLT) during the first 28-day cycle of treatment

Recruiting

Share